Survival benefit from abemaciclib in non-small cell lung cancer by Kirsten rat sarcoma-mutation gene expression subtype: retrospective analysis from the JUNIPER Trial
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Patients with KRAS-mutated non-small cell lung cancer and KL expression subtype tumors may benefit from abemaciclib over erlotinib, showing improved overall survival (OS) and progression-free survival (PFS). Further validation is recommended.
Area Of Science
- Oncology
- Genomics
- Pharmacology
Background
- The JUNIPER trial investigated abemaciclib versus erlotinib in advanced non-small cell lung cancer (NSCLC) with KRAS mutations.
- While the trial showed prolonged progression-free survival (PFS), overall survival (OS) benefits were not consistently observed.
Purpose Of The Study
- To retrospectively evaluate if specific KRAS co-mutation gene expression subtypes in NSCLC patients benefit from abemaciclib.
- To assess abemaciclib efficacy within distinct patient subgroups based on gene expression profiles.
Main Methods
- Tumor specimens from 148 JUNIPER trial patients were analyzed for gene expression.
- Samples were classified into three subtypes: KL, KP, and K.
- OS and PFS were assessed for each subtype in patients receiving abemaciclib or erlotinib.
Main Results
- Patients with the KL subtype showed a significant OS advantage with abemaciclib versus erlotinib (median 13.05 vs 5.65 months).
- Both KL and KP subtypes demonstrated PFS benefits with abemaciclib.
- The K subtype showed no OS or PFS benefit from abemaciclib.
Conclusions
- The KL expression subtype may predict a better OS and PFS response to abemaciclib in KRAS-mutated NSCLC.
- These findings suggest a potential role for gene expression profiling in guiding treatment decisions.
- Independent validation of these results is warranted.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...